{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T15:47:42Z","timestamp":1774712862754,"version":"3.50.1"},"reference-count":24,"publisher":"Mattioli1885","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Introduction: the oral health in psoriatic patients seems to be compromised respect to control individuals: many published studies have investigated the relationship between psoriatic disease and gingivitis, periodontitis, and missing teeth. However, data from these studies are not yet consistent and exhaustive. Moreover, no studies have considered the possible specific effects of conventional and biological systemic psoriatic treatments. Object: we report a narrative review of the literature about the possible link between anti-psoriatic drugs and oral disease onset, and case series of patients that have experienced oral disease during systemic therapy for psoriasis. Methods: this is a narrative review. The literature search was performed using MEDLINE databases. From the selected articles, additional references were identified by a manual search among the cited literature. Results: Oral adverse events during psoriatic therapies can be found as sporadic cases. The specific mechanisms of interplay between oral anatomic structures and the pathway targeted by the systemic agents will be deeply investigated. Conclusion: It should be recommended to all psoriatic patients who are candidates for conventional or biological systemic therapy to examine their oral state by a dentist and dermatologist with regular follow-up, to prevent oral health complications. Dermatologists and oral medicine specialists should be ready to recognize and manage this increasing number of oral adverse drug reactions during systemic treatments for psoriatic disease, providing patients with sufficient information about this risk and stressing the fundamental importance of regular dental assessments, and good oral hygiene.<\/jats:p>","DOI":"10.5826\/dpc.1402a107","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T12:39:33Z","timestamp":1718627973000},"page":"e2024107","source":"Crossref","is-referenced-by-count":3,"title":["Oral Diseases During Systemic Psoriatic Drugs: A Review of the Literature and Case Series"],"prefix":"10.5826","volume":"14","author":[{"given":"Annunziata","family":"Raimondo","sequence":"first","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, \u201cScuola Medica Salernitana\u201d, University of Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Di Spirito","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, \u201cScuola Medica Salernitana\u201d, University of Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Lembo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, \u201cScuola Medica Salernitana\u201d, University of Salerno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27750","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"10.5826\/dpc.1402a107_ref1","doi-asserted-by":"crossref","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957\u2013970. PMID: 28273019 DOI: 10.1056\/NEJMra1505557","DOI":"10.1056\/NEJMra1505557"},{"key":"10.5826\/dpc.1402a107_ref2","doi-asserted-by":"crossref","unstructured":"Kamiya, K.; Kishimoto, M.; Sugai, J.; Komine, M.; Ohtsuki, M. Risk Factors for the Development of Psoriasis. Int. J. Mol. Sci. 2019;20(18):4347. PMID: 31491865 PMCID: PMC6769762 DOI: 10.3390\/ijms20184347","DOI":"10.3390\/ijms20184347"},{"key":"10.5826\/dpc.1402a107_ref3","doi-asserted-by":"crossref","unstructured":"Olejnik, M.; Osmola-Man \u0301kowska, A.; S \u0301lebioda, Z.; Adamski, Z.; Dorocka-Bobkowska, B. Oral Mucosal Lesions in Psoriatic Patients Based on Disease Severity and Treatment Approach. J. Oral Pathol. Med. Off. Publ. Int. Assoc. Oral Pathol. Am. Acad. Oral Pathol. 2020;49(8): 822\u2013828.","DOI":"10.1111\/jop.13095"},{"key":"10.5826\/dpc.1402a107_ref4","doi-asserted-by":"crossref","unstructured":"Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol Ther. 2016;3(1):91\u2013102. PMID: 33245622 DOI: 10.1111\/jop.13095","DOI":"10.1007\/s40744-016-0029-z"},{"key":"10.5826\/dpc.1402a107_ref5","doi-asserted-by":"crossref","unstructured":"Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53(4):573. PMID: 16198775 DOI: 10.1016\/j.jaad.2005.03.046","DOI":"10.1016\/j.jaad.2005.03.046"},{"key":"10.5826\/dpc.1402a107_ref6","doi-asserted-by":"crossref","unstructured":"Wilson FC, Icen M, Crowson CS, et al. Incidence and Clinical Predictors of Psoriatic Arthritis in Patients With Psoriasis: A Population-Based Study. Arthritis Rheum. 2009;61(2):233-239. PMID: 19177544 PMCID: PMC3061343 DOI: 10.1002\/art.24172","DOI":"10.1002\/art.24172"},{"key":"10.5826\/dpc.1402a107_ref7","doi-asserted-by":"crossref","unstructured":"Nijakowski K, Gruszczy\u0144ski D, Kolasi\u0144ska J, Kopa\u0142a D, Surdacka A. Periodontal Disease in Patients with Psoriasis: A Systematic Review. Int J Environ Res Public Health. 2022;19(18):11302. PMID: 36141573 PMCID: PMC9516998 DOI: 10.3390\/ijerph191811302","DOI":"10.3390\/ijerph191811302"},{"key":"10.5826\/dpc.1402a107_ref8","doi-asserted-by":"crossref","unstructured":"Kinane, D.F.; Stathopoulou, P.G.; Papapanou, P.N. Periodontal Diseases. Nat. Rev. Dis. Primer 2017;3:17038. PMID: 28805207 DOI: 10.1038\/nrdp.2017.38","DOI":"10.1038\/nrdp.2017.38"},{"key":"10.5826\/dpc.1402a107_ref9","doi-asserted-by":"crossref","unstructured":"Lee CS, Li K. A review of acitretin for the treatment of psoriasis. Expert Opin Drug Saf. 2009;8(6):769-79. PMID: 19998529 DOI: 10.1517\/14740330903393732","DOI":"10.1517\/14740330903393732"},{"key":"10.5826\/dpc.1402a107_ref10","doi-asserted-by":"crossref","unstructured":"Colombo MD, Cassano N, Bellia G, Vena GA. Cyclosporine regimens in plaque psoriasis: an overview with special emphasis on dose, duration, and old and new treatment approaches. ScientificWorldJournal. 2013;2013:805705. PMID: 23983647 PMCID: PMC3745987 DOI: 10.1155\/2013\/805705","DOI":"10.1155\/2013\/805705"},{"key":"10.5826\/dpc.1402a107_ref11","doi-asserted-by":"crossref","unstructured":"Lauritano D, Palmieri A, Lucchese A, Di Stasio D, Moreo G, Carinci F. Role of Cyclosporine in Gingival Hyperplasia: An In Vitro Study on Gingival Fibroblasts. Int J Mol Sci. 2020;21(2):595. PMID: 31963361 PMCID: PMC7014429 DOI: 10.3390\/ijms21020595","DOI":"10.3390\/ijms21020595"},{"key":"10.5826\/dpc.1402a107_ref12","doi-asserted-by":"crossref","unstructured":"Colombo D, Banfi G, Cassano N, Graziottin A, Vena GA, Fiori GG, Zagni E, Stingeni L, Chimenti S, Berardesca E, Micali G, Albertini G, De Simone C, Bellia G; GENDER ATTENTION study group. The GENDER ATTENTION Observational Study: Gender and Hormonal Status Differences in the Incidence of Adverse Events During Cyclosporine Treatment in Psoriatic Patients. Adv Ther. 2017 ;34(6):1349-1363. PMID: 28432647 PMCID: PMC5487861 DOI: 10.1007\/s12325-017-0526-7","DOI":"10.1007\/s12325-017-0526-7"},{"key":"10.5826\/dpc.1402a107_ref13","doi-asserted-by":"crossref","unstructured":"Dhir V, Sandhu A, Kaur J, Pinto B, Kumar P, Kaur P, et al. Comparison of two different folic acid doses with methotrexate--a randomized controlled trial (FOLVARI Study). Arthritis Res Ther. 2015;17:156. PMID: 26063325 PMCID: PMC4483203 DOI: 10.1186\/s13075-015-0668-4","DOI":"10.1186\/s13075-015-0668-4"},{"key":"10.5826\/dpc.1402a107_ref14","doi-asserted-by":"crossref","unstructured":"Lalani R, Lyu H, Vanni K, Solomon DH. Low-Dose Methotrexate and Mucocutaneous Adverse Events: Results of a Systematic Literature Review and Meta-Analysis of Randomized Controlled Trials. Arthritis Care Res (Hoboken). 2020;72(8):1140-1146. PMID: 31150157 PMCID: PMC6885092 DOI: 10.1002\/acr.23999","DOI":"10.1002\/acr.23999"},{"key":"10.5826\/dpc.1402a107_ref15","doi-asserted-by":"crossref","unstructured":"Deeming GM, Collingwood J, Pemberton MN. Methotrexate and oral ulceration. Br Dent J. 2005;198(2):83-5. PMID: 15702101 DOI: 10.1038\/sj.bdj.4811972","DOI":"10.1038\/sj.bdj.4811972"},{"key":"10.5826\/dpc.1402a107_ref16","doi-asserted-by":"crossref","unstructured":"Lembo S, Martora F, Grimaldi A, Raimondo A. Cutaneous Eruption after SARS-CoV-2 Vaccine in Psoriatic Patient Treated with Methotrexate. Indian J Dermatol. 2022;67(5):626. PMID: 36865874 PMCID: PMC9971768 DOI: 10.4103\/ijd.ijd_361_22","DOI":"10.4103\/ijd.ijd_361_22"},{"key":"10.5826\/dpc.1402a107_ref17","doi-asserted-by":"crossref","unstructured":"De Smit MJ, Westra J, Posthumus MD, Springer G, van Winkelhoff AJ, Vissink A, Brouwer E, Bijl M. Effect of Anti-Rheumatic Treatment on the Periodontal Condition of Rheumatoid Arthritis Patients. Int J Environ Res Public Health. 2021;18(5):2529. PMID: 33806304 PMCID: PMC7967392 DOI: 10.3390\/ijerph18052529","DOI":"10.3390\/ijerph18052529"},{"key":"10.5826\/dpc.1402a107_ref18","doi-asserted-by":"crossref","unstructured":"Lakio, L.; Antinheimo, J.; Paju, S.; Buhlin, K.; Pussinen, P.J.; Alfthan, G. Tracking of plasma antibodies against Aggregati-bacter actinomycetemcomitans and Porphyromonas gingivalis during 15 years. J. Oral Microbiol. 2009, 1. PMID: 21523211 PMCID: PMC3077000 DOI: 10.3402\/jom.v1i0.1979","DOI":"10.3402\/jom.v1i0.1979"},{"key":"10.5826\/dpc.1402a107_ref19","doi-asserted-by":"crossref","unstructured":"Tachibana M, Yonemoto Y, Okamura K, Suto T, Sakane H, Kaneko T, Dam TT, Okura C, Tajika T, Tsushima Y, Chikuda H. Does periodontitis affect the treatment response of biologics in the treatment of rheumatoid arthritis? Arthritis Res Ther. 2020;22(1):178. PMID: 32711580 PMCID: PMC7382136 DOI: 10.1186\/s13075-020-02269-x","DOI":"10.1186\/s13075-020-02269-x"},{"key":"10.5826\/dpc.1402a107_ref20","doi-asserted-by":"crossref","unstructured":"Picciani BL, Michalski-Santos B, Carneiro S, Sampaio AL, Avelleira JC, Azulay DR, Pinto JM, Dias EP. Oral candidiasis in patients with psoriasis: correlation of oral examination and cytopathological evaluation with psoriasis disease severity and treatment. J Am Acad Dermatol. 2013;68(6):986-991. PMID: 23384796 DOI: 10.1016\/j.jaad.2012.11.033","DOI":"10.1016\/j.jaad.2012.11.033"},{"key":"10.5826\/dpc.1402a107_ref21","doi-asserted-by":"crossref","unstructured":"Picciani BLS, Dziedzic A, Werneck JT, Marinho MA, Dick TNA, Quintanilha NR, Dias EP. Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab). BMC Oral Health. 2021;21(1):292. PMID: 34103043 PMCID: PMC8186152 DOI: 10.1186\/s12903-021-01653-6","DOI":"10.1186\/s12903-021-01653-6"},{"key":"10.5826\/dpc.1402a107_ref22","doi-asserted-by":"crossref","unstructured":"Raimondo A, Salzano FA, Lembo S. Disseminated mucocutaneous Candida infection during anti IL-17A therapy in a psoriatic patient. Ital J Dermatol Venerol. 2021;156(3):400-401. PMID: 33228332 DOI: 10.23736\/S2784-8671.20.06673-0","DOI":"10.23736\/S2784-8671.20.06673-0"},{"key":"10.5826\/dpc.1402a107_ref23","doi-asserted-by":"crossref","unstructured":"Qamar Z, Alghamdi AMS, Haydarah NKB, Balateef AA, Alamoudi AA, Abumismar MA, Shivakumar S, Cicci\u00f9 M, Minervini G. Impact of temporomandibular disorders on oral health-related quality of life: A systematic review and meta-analysis. J Oral Rehabil. 2023;50(8):706-714. doi: 10.1111\/joor.13472. PMID: 37078711","DOI":"10.1111\/joor.13472"},{"key":"10.5826\/dpc.1402a107_ref24","unstructured":"Nazir MA. Prevalence of periodontal disease, its association with systemic diseases and prevention. Int J Health Sci (Qassim). 2017;11(2):72-80. PMID: 28539867 PMCID: PMC5426403"}],"container-title":["Dermatology Practical &amp; Conceptual"],"original-title":[],"link":[{"URL":"https:\/\/mail.dpcj.org\/index.php\/dpc\/article\/download\/3707\/2689","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/mail.dpcj.org\/index.php\/dpc\/article\/download\/3707\/2820","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/mail.dpcj.org\/index.php\/dpc\/article\/download\/3707\/2689","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T05:06:54Z","timestamp":1723093614000},"score":1,"resource":{"primary":{"URL":"https:\/\/mail.dpcj.org\/index.php\/dpc\/article\/view\/3707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.5826\/dpc.1402a107","relation":{"has-manifestation":[{"id-type":"other","id":"1-72-3707-g2689 10.5826\/","asserted-by":"subject"},{"id-type":"other","id":"1-72-3707-g2820","asserted-by":"subject"}],"is-part-of":[{"id-type":"other","id":"1-72 10.5826\/","asserted-by":"subject"}]},"ISSN":["2160-9381"],"issn-type":[{"value":"2160-9381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"article-number":"3"}}